HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via ISI Web of Science (5) Citing Articles via Google Scholar Google Scholar Articles by Zambarakji, H. J. Articles by Miller, J. W. Search for Related Content PubMed PubMed Citation Articles by Zambarakji, H. J. Articles by Miller, J. W.

Dose-Dependent Effect of Pitavastatin on VEGF and Angiogenesis in a Mouse Model of Choroidal Neovascularization

¹From the Angiogenesis Laboratory and ²Retina Service, Massachusetts Eye and Ear Infirmary, Harvard Medical School, Boston, Massachusetts.

PURPOSE. To evaluate the relation between statin therapy, vascular endothelial growth factor (VEGF) expression, vascular leakage, and CNV size in experimentally induced choroidal neovascularization (CNV).

METHODS. Wild-type (C57 Bl/6J) mice received pitavastatin 0.18 mg/kg per day (group 1), 1.8 mg/kg per day (group 2) or 18 mg/kg per day (group 3) for 3 days before laser-induced CNV and continued to receive the drug for 14 days. Serum total cholesterol levels were measured by spectrophotometry. Fluorescein angiograms were graded by masked observers. VEGF protein levels from retinal lysates were measured and CNV area was assessed by histology.

RESULTS. Pitavastatin did not reduce total serum cholesterol at any of the doses used. The incidence rate ratios for development of clinically significant CNV leakage was 0.62 (95% CI, 0.46–0.84) for group 1, 0.56 (95% CI, 0.28–1.10) for group 2, and 1.22 (95% CI, 1.01–1.48) for group 3 (P = 0.002, 0.09, and 0.04, respectively). Mean CNV area increased by 13%, 22%, and 95% in groups 1, 2, and 3, respectively (P > 0.05). Normalized VEGF levels did not mirror the observed changes in fluorescein leakage and CNV area in histologic examination.

CONCLUSIONS. Pitavastatin therapy for experimental CNV in wild-type mice resulted in reduced fluorescein leakage at a dose of 0.18 mg/kg per day. The higher dose of 18 mg/kg per day resulted in increased fluorescein leakage and a trend toward an increase in CNV size, indicating a potentiating effect in choroidal neovascular disease.

This article has been cited by other articles:

				H. She, T. Nakazawa, A. Matsubara, T. Hisatomi, T. A. Young, N. Michaud, E. Connolly, A. Hafezi-Moghadam, E. S. Gragoudas, and J. W. Miller Reduced Photoreceptor Damage after Photodynamic Therapy through Blockade of Nitric Oxide Synthase in a Model of Choroidal Neovascularization Invest. Ophthalmol. Vis. Sci., May 1, 2007; 48(5): 2268 - 2277. [Abstract] [Full Text] [PDF]

				K. Yamada, E. Sakurai, M. Itaya, S. Yamasaki, and Y. Ogura Inhibition of Laser-Induced Choroidal Neovascularization by Atorvastatin by Downregulation of Monocyte Chemotactic Protein-1 Synthesis in Mice Invest. Ophthalmol. Vis. Sci., April 1, 2007; 48(4): 1839 - 1843. [Abstract] [Full Text] [PDF]